STOCK TITAN
  1. Home
  2. Sec-filings
  3. MEDP
  4. [Form 4] Medpace Holdings, Inc. Insider Trading Activity

Medpace (MEDP) director sells 7,283 shares after option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

For Medpace Holdings, Inc. (MEDP), director Fred B. Davenport Jr. reported exercising stock options for a total of 7,583 shares of common stock on 2026-08-19 at exercise prices of $84.36, $133.87 and $164.68 per share. On the same date, he sold 7,283 shares of common stock at a weighted average price of $606.15 per share, in multiple trades between $605.59 and $607.20. Following these transactions, 2,000 shares are reported as held indirectly by a trust for his benefit.

Positive

  • None.

Negative

  • None.
Insider DAVENPORT FRED B JR
Role Director
Sold 7,283 shs ($4.41M)
Approx. gross sale proceeds $4.41M
Approx. exercise cost $880K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F3 1,903 $0.00 $0.00
Exercise Stock Option (Right to Buy) F4 3,858 $0.00 $0.00
Exercise Stock Option (Right to Buy) F5 1,822 $0.00 $0.00
Exercise Common Stock 1,903 $133.87 $255K
Exercise Common Stock 3,858 $84.36 $325K
Exercise Common Stock 1,822 $164.68 $300K
Sale Common Stock F1 7,283 $606.15 $4.41M
holding Common Stock F2 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 3,798 shares (Direct); Common Stock — 2,000 shares (Indirect, By Trust)
Footnotes (5)
  1. F1. The reported price is a weighted average price. The shares were sold in multiple transactions ranging from $605.59 to $607.202. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
  2. F2. Owned by trust for the benefit of the Reporting Person.
  3. F3. The option vested in full on 05/18/2023.
  4. F4. The option vested in full on 05/13/2021.
  5. F5. The option vested in full on 05/14/2022.
Shares sold 7,283 shares Common stock sold on 2026-08-19
Weighted average sale price $606.15 per share Sale of 7,283 common shares; trades ranged $605.59–$607.20
Options exercised (total shares) 7,583 shares Stock options exercised on 2026-08-19
Option exercise price $133.87 per share Stock Option (Right to Buy) expiring 2029-05-20
Option exercise price $84.36 per share Stock Option (Right to Buy) expiring 2027-05-15
Option exercise price $164.68 per share Stock Option (Right to Buy) expiring 2028-05-14
Indirect holdings by trust 2,000 shares Common stock owned by trust for the benefit of the Reporting Person
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
weighted average price financial
"The reported price is a weighted average price. The shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect financial
"total_shares_following_transaction 2000.0000, direct_or_indirect I, nature_of_ownership"
nature of ownership financial
"nature_of_ownership By Trust with footnote Owned by trust"

FAQ

What transactions did MEDP director Fred B. Davenport Jr. report on this Form 4?
He reported exercising options for 7,583 shares of Medpace Holdings, Inc. common stock and selling 7,283 shares of common stock on 2026-08-19, with remaining 2,000 shares held indirectly by a trust for his benefit.

How many Medpace (MEDP) shares did Davenport sell and at what price?
He sold 7,283 shares of Medpace common stock at a weighted average price of $606.15 per share, in multiple transactions with prices ranging from $605.59 to $607.20.

What option exercise prices were involved in Davenport’s MEDP Form 4?
He exercised stock options covering 7,583 shares at exercise prices of $84.36, $133.87 and $164.68 per share, each corresponding to separate option grants that had fully vested before the reported transactions.

How many Medpace (MEDP) shares does Davenport hold through a trust?
The filing reports 2,000 shares of Medpace common stock held indirectly "by trust for the benefit of the Reporting Person," indicating trust ownership rather than direct personal holding.

Were Davenport’s MEDP sales under a Rule 10b5-1 trading plan?
The Form 4’s Rule 10b5-1 checkbox is not checked, and the footnotes do not mention any Rule 10b5-1 trading plan, so the reported transactions are not identified as being made under such a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DAVENPORT FRED B JR
(Last)(First)(Middle)
C/O MEDPACE HOLDINGS, INC.
5375 MEDPACE WAY
(Street)
CINCINNATI OHIO 45227
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/19/2026M1,903A$133.875,401D
Common Stock08/19/2026M3,858A$84.369,259D
Common Stock08/19/2026M1,822A$164.6811,081D
Common Stock08/19/2026S7,283D$606.15(1)3,798D
Common Stock2,000IBy Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$133.8708/19/2026M1,903 (3)05/20/2029Common Stock1,903$00D
Stock Option (Right to Buy)$84.3608/19/2026M3,858 (4)05/15/2027Common Stock3,858$00D
Stock Option (Right to Buy)$164.6808/19/2026M1,822 (5)05/14/2028Common Stock1,822$00D
Explanation of Responses:
1. The reported price is a weighted average price. The shares were sold in multiple transactions ranging from $605.59 to $607.202. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
2. Owned by trust for the benefit of the Reporting Person.
3. The option vested in full on 05/18/2023.
4. The option vested in full on 05/13/2021.
5. The option vested in full on 05/14/2022.
/s/ Stephen P. Ewald, Attorney-in-Fact for Fred B. Davenport Jr.08/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR